From March 2018 through April 2020, 150 patients received a single infusion of pafolacianine (safety analysis set); 109 patients with folate receptor–positive ovarian cancer comprised the full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback